These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2265462)

  • 21. Clinical trial of iproplatin (cis-dichloro-trans-dihydroxy-bis-isopropylamine platinum IV, CHIP) in patients with advanced breast cancer.
    Casper ES; Smart TC; Hakes TB; Ochoa M; Kaufman RJ
    Invest New Drugs; 1988 Jun; 6(2):87-91. PubMed ID: 3049433
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platinum(II) catalysis and radical intervention in reductions of platinum(IV) antitumor drugs by ascorbic acid.
    Weaver EL; Bose RN
    J Inorg Biochem; 2003 Jul; 95(4):231-9. PubMed ID: 12818793
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cycloplatam and oxoplatin--the new antitumor platinum compounds of the second generation.
    Presnov MA; Konovalova AL
    Arch Geschwulstforsch; 1988; 58(1):43-9. PubMed ID: 3285804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
    Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
    Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
    Mellish KJ; Kelland LR; Harrap KR
    Br J Cancer; 1993 Aug; 68(2):240-50. PubMed ID: 8347478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
    Raynaud FI; Odell DE; Kelland LR
    Br J Cancer; 1996 Aug; 74(3):380-6. PubMed ID: 8695352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytotoxicity, cellular uptake, glutathione and DNA interactions of an antitumor large-ring Pt II chelate complex incorporating the cis-1,4-diaminocyclohexane carrier ligand.
    Kasparkova J; Suchankova T; Halamikova A; Zerzankova L; Vrana O; Margiotta N; Natile G; Brabec V
    Biochem Pharmacol; 2010 Feb; 79(4):552-64. PubMed ID: 19782655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease.
    Thatcher N; Sharma H; Harrison R; Smith A; Zaki A; McAuliffe CA; Crowther D; Fox BW
    Cancer Chemother Pharmacol; 1982; 9(1):13-6. PubMed ID: 6890414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
    Kasparkova J; Marini V; Najajreh Y; Gibson D; Brabec V
    Biochemistry; 2003 May; 42(20):6321-32. PubMed ID: 12755637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparative binding of platinum anti-tumour compounds to plasma proteins in the rat (in vivo) and mouse (in vitro).
    Perera A; Jackson H; Sharma HL; McAuliffe CA; Fox BW
    Chem Biol Interact; 1992 Dec; 85(2-3):199-213. PubMed ID: 1493609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracellular glutathione and cytotoxicity of platinum complexes.
    Pendyala L; Creaven PJ; Perez R; Zdanowicz JR; Raghavan D
    Cancer Chemother Pharmacol; 1995; 36(4):271-8. PubMed ID: 7628045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sister chromatid exchanges induced by two radiosensitizing platinum compounds (cis-dichloro-bis isopropylamine trans dihydroxy platinum IV (CHIP) and cis platinum metronidazole2Cl2(FLAP)) in CHO cells in vitro.
    Bocian E; Laverick M; Nias AH
    Br J Cancer; 1983 Dec; 48(6):803-7. PubMed ID: 6652019
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical development of iproplatin (CHIP).
    Creaven PJ; Pendyala L; Madajewicz S
    Drugs Exp Clin Res; 1986; 12(1-3):287-92. PubMed ID: 3732051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats.
    Láznícková A; Láznícek M; Kvĕtina J; Drobník J
    Cancer Chemother Pharmacol; 1986; 17(2):133-6. PubMed ID: 3521926
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds.
    Meijer C; Mulder NH; Timmer-Bosscha H; Sluiter WJ; Meersma GJ; de Vries EG
    Cancer Res; 1992 Dec; 52(24):6885-9. PubMed ID: 1458477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of platinum concentrations in human head and neck tumours following administration of carboplatin, iproplatin or cisplatin.
    Hecquet B; Caty A; Fournier C; Lefebvre JL; Adenis L
    Bull Cancer; 1987; 74(4):433-6. PubMed ID: 3311237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of the bidentate malonate ligand on the utilization and cytotoxicity of platinum compounds in the L1210 cell line.
    Mauldin SK; Husain I; Sancar A; Chaney SG
    Cancer Res; 1986 Jun; 46(6):2876-82. PubMed ID: 3698013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles.
    Dedon PC; Borch RF
    Biochem Pharmacol; 1987 Jun; 36(12):1955-64. PubMed ID: 2954556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combining the platinum(ii) drug candidate kiteplatin with 1,10-phenanthroline analogues.
    Pages BJ; Sakoff J; Gilbert J; Zhang Y; Kelly SM; Hoeschele JD; Aldrich-Wright JR
    Dalton Trans; 2018 Feb; 47(7):2156-2163. PubMed ID: 29192713
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An autoradiographic study of the intrarenal localisation and retention of cisplatin, iproplatin and paraplatin.
    Ewen C; Perera A; Hendry JH; McAuliffe CA; Sharma H; Fox BW
    Cancer Chemother Pharmacol; 1988; 22(3):241-5. PubMed ID: 3044632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.